Cost-Effectiveness of Radar: An Innovative Model to Organize Diabetes Care in First Nations Communities in Canada
Speaker(s)
Ghule P1, Teali IR1, Minhas-Sandhu J2, Crowshoe L3, Johnson JA2, Samanani S4, Eurich DT2, Asche C1
1University of Utah, Salt Lake City, UT, USA, 2University of Alberta, Edmonton, AB, Canada, 3University of Calgary, Calgary, AB, Canada, 4Okaki, Calgary, AB, Canada
Presentation Documents
OBJECTIVES: RADAR (Reorganizing the Approach to Diabetes through the Application of Registries) is an innovative care model that incorporates a disease registry and electronic health record for local care provision with remote coordination tailored for First Nation (FN) people in Alberta, Canada. RADAR improved outcomes with patients achieving 10% improvement in HbA1c, SBP, and/or LDL cholesterol. This study aimed to evaluate the cost-effectiveness of RADAR compared with existing baseline diabetes care in FNS with type 2 diabetes (T2DM).
METHODS: We used the United Kingdom Prospective Diabetes Study (UKPDS) OM 2 for this CEA. Demographics like age, gender, and clinical parameters height, weight, diabetes duration, LDL, HDL, SBP, HbA1c, and eGFR of RADAR users relative to their baseline status (n=516) were used as input parameters for the model. Other input parameters like cost and utility were taken from literature. Outcome measures included life years (LY’s), quality-adjusted life expectancy (QALE), total costs, and complication rates. The base-case analysis was conducted using a Canadian payer perspective with a 70-year time horizon. Costs and effects were discounted at 3.5% annually.
RESULTS: Discounted life expectancy at baseline was 14.78 (95% CI 14.50,15.25), and after RADAR was 14.66 (95% CI 14.40,15.13). Discounted QALE at baseline was 14.59 (95% CI 14.31,15.06) and after RADAR was 14.46 (95% CI 14.20,14.92). The incremental cost of the intervention was $4546. There was no significant difference in the incidence of IHD, MI, heart failure, stroke, and renal failure over 70 years between the RADAR and non-RADAR users. Routine care alone dominated over RADAR users with an ICER of -$37,833/QALE gained.
CONCLUSIONS: RADAR improved immediate clinical outcomes in the FN population in Canada over 2 years, however, this was associated with an increase in costs. Given the fragmented care for FN people, additional costs to improve outcomes is warranted to ensure equitable healthcare in Canada.
Code
EE391
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)